Evidence map›Paper›PMID 32573897›Full record

ArticleJournal of thrombosis and haemostasis : JTH2020

High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Erica M Sparkenbaugh, Malgorzata Kasztan, Michael W Henderson, Patrick Ellsworth, Parker Ross Davis, Kathryn J Wilson, Brandi Reeves, Nigel S Key, Sidney Strickland, Keith McCrae and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Erica M SparkenbaughUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-5529-7847
Malgorzata KasztanSection of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-3345-1580
Michael W HendersonUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Patrick EllsworthUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Parker Ross DavisSection of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Kathryn J WilsonUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Brandi ReevesUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-2106-3698
Nigel S KeyUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-8930-4304
Sidney StricklandPatricia and John Rosenwald Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-3072-9244
Keith McCraeDepartment of Hematology Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-7340-475X
David M PollockSection of Cardio-Renal Physiology and Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-7546-6003
Rafal PawlinskiUNC Blood Research Center, Division of Hematology & Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5162-7135
University of North Carolina at Chapel Hill · USUniversity of Alabama at Birmingham · USCleveland Clinic · USRockefeller University · US

Funding

UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Venkata Saroja Voruganti · 1999 to 2026
$31.6M
Research Training in Hematology at UNC Chapel HillT32HL007149 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nigel S. Key · 1985 to 2026
$8.6M
The Role of Endothelin-1 in Sickle Cell DiseaseU01HL117684 · NHLBI · AUGUSTA UNIVERSITY · PI KUTLAR, ABDULLAH, MEILER, STEFFEN · 2013 to 2017
$8.1M
Targeted Anticoagulant Therapy for Sickle Cell DiseaseU01HL117659 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S., MACKMAN, NIGEL · 2013 to 2017
$7.6M
Role of the Contact System in Alzheimer's DiseaseR01NS102721 · NINDS · ROCKEFELLER UNIVERSITY · PI Erin H. Norris, SIDNEY STRICKLAND · 2018 to 2026
$5.3M
Mechanism of sickle cell disease-specific venous thromboembolismR01HL157441 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S., PAWLINSKI, RAFAL L · 2021 to 2024
$2.6M
Mechanisms of coagulation-dependent pathologies in sickle cell diseaseR01HL142604 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAWLINSKI, RAFAL L · 2018 to 2021
$1.6M
Fibrinolysis Evaluation in A-TREAT (‘FEAT’ Study)R01HL146226 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEY, NIGEL S. · 2019 to 2021
$1.2M
The Role of Endothelin-1 in Tubular Injury in Sickle Cell DiseaseR00HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2021 to 2023
$747k
The role of endothelin-1 in tubular injury in sickle cell diseaseK99HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2019 to 2020
$306k
American Heart Association 16POST30230002NHLBI NIH HHS K99 HL144817NHLBI NIH HHS R00 HL144817NHLBI NIH HHS R01 HL142604NHLBI NIH HHS R01 HL146226NHLBI NIH HHS R01 HL157441NHLBI NIH HHS T32 HL007149NHLBI NIH HHS U01 HL117659NHLBI NIH HHS U01 HL117684NIDDK NIH HHS P30 DK056350NINDS NIH HHS R01 NS102721NINDS NIH HHS R01NS102721
6 · The paper itself

Abstract

backgroundSickle cell disease (SCD) is characterized by chronic hemolytic anemia, vaso-occlusive crises, chronic inflammation, and activation of coagulation. The clinical complications such as painful crisis, stroke, pulmonary hypertension, nephropathy and venous thromboembolism lead to cumulative organ damage and premature death. High molecular weight kininogen (HK) is a central cofactor for the kallikrein-kinin and intrinsic coagulation pathways, which contributes to both coagulation and inflammation.

objectiveWe hypothesize that HK contributes to the hypercoagulable and pro-inflammatory state that causes end-organ damage and early mortality in sickle mice.

methodsWe evaluated the role of HK in the Townes mouse model of SCD. RESULTS/

conclusionsWe found elevated plasma levels of cleaved HK in sickle patients compared to healthy controls, suggesting ongoing HK activation in SCD. We used bone marrow transplantation to generate wild type and sickle cell mice on a HK-deficient background. We found that short-term HK deficiency attenuated thrombin generation and inflammation in sickle mice at steady state, which was independent of bradykinin signaling. Moreover, long-term HK deficiency attenuates kidney injury, reduces chronic inflammation, and ultimately improves survival of sickle mice.

Indexed as

Anemia, Sickle CellKininogen, High-Molecular-WeightAnimalsBlood CoagulationHumansKidneyMiceThrombinKininogen, High-Molecular-WeightThrombinanemiablood coagulationhigh molecular weightinflammationkidney diseasekininogensickle cell

Identifiers

PMID32573897
PMCPMC8043232
OpenAlexW3036877578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.